Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial-Reference-Cited by-同舟云学术

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

Published:2016-11 Issue:11 Volume:17 Page:1579-1589
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ledermann Jonathan A,Harter Philipp,Gourley Charlie,Friedlander Michael,Vergote Ignace,Rustin Gordon,Scott Clare,Meier Werner,Shapira-Frommer Ronnie,Safra Tamar,Matei Daniela,Fielding Anitra,Spencer Stuart,Rowe Philip,Lowe Elizabeth,Hodgson Darren,Sovak Mika A,Matulonis Ursula

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

3. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments;Kyrgiou;J Natl Cancer Inst,2006

4. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study;de Angelis;Lancet Oncol,2014

5. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer;Ledermann;N Engl J Med,2012

Cited by 381 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report;Gynecologic Oncology;2024-11

2. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26

3. “Having cancer is very expensive”: A qualitative study of patients with ovarian cancer and PARP inhibitor treatment;Gynecologic Oncology;2024-07

4. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial;eClinicalMedicine;2024-06

5. Targeting SCD triggers lipotoxicity of cancer cells and enhances anti-tumor immunity in breast cancer brain metastasis mouse models;2024-05-09